Caris Life Sciences, Inc.
CAI
$24.03
-$0.79-3.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 21.99% | -26.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.99% | -26.19% | |||
| Cost of Revenue | 12.42% | 6.74% | |||
| Gross Profit | 27.06% | -36.55% | |||
| SG&A Expenses | 14.86% | 0.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.28% | 3.14% | |||
| Operating Income | 409.77% | -94.03% | |||
| Income Before Tax | 4.66% | -100.79% | |||
| Income Tax Expenses | 117.16% | -- | |||
| Earnings from Continuing Operations | -24.90% | -100.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.90% | -100.62% | |||
| EBIT | 409.77% | -94.03% | |||
| EBITDA | 223.42% | -88.84% | |||
| EPS Basic | -27.78% | -100.62% | |||
| Normalized Basic EPS | 3,985.71% | -100.75% | |||
| EPS Diluted | -27.78% | -100.65% | |||
| Normalized Diluted EPS | 3,985.71% | -100.79% | |||
| Average Basic Shares Outstanding | 0.12% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.12% | -4.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||